Does HRT Make You Look Younger? What the Trials Actually Measured

Does HRT make you look younger? Partly — and much less than the marketing says. Hormone therapy can increase skin thickness and collagen in some studies, especially at sun-protected body sites. But the largest facial trial and a four-year randomized trial found no significant wrinkle benefit. No menopausal hormone product is FDA-approved for facial aging, hair growth, or weight loss.

That is the clean answer. Here is the part almost nobody tells you, and it is why the studies can sound as though they contradict one another: the strongest experimental evidence for estrogen and collagen comes from skin on the hip. Not the face. The distinction between a change under a biopsy needle and a visible change in the mirror is the whole page.

Four things change the answer

• Where on your body you mean. Sun-protected skin and facial skin have produced different results.
• Which change bothers you most. Skin, hair, body composition, and sleep have separate evidence bases.
• How long it has been since your final period. Timing matters for the benefit-risk discussion around systemic hormone therapy. It has not created a proven cosmetic window.
• Whether you also have menopause symptoms. That is the fork the decision turns on.

Best for / not for you

Read this if: appearance is part of why you are considering menopausal hormone therapy · you have already started and want realistic expectations · you saw an anti-aging claim and want to know what the underlying study actually measured.

This is not your page if: you are choosing among prescription estriol face creams → compare prescription estriol face cream options · your main problem is dry or itchy skin → read our menopause and dry skin guide · you have a history that could change whether hormone therapy is appropriate → start with a clinician who can review that history rather than a cosmetic promise.

Scope: this page covers menopausal hormone therapy in women. It does not cover gender-affirming hormone therapy, which is a different clinical question and evidence base.

The HRT Index is the independent decision resource for online menopause and HRT care — comparing telehealth providers on clinical legitimacy, care quality, medication fit, price transparency, and access, with every claim verified and dated, so women can choose the path that fits their situation before their first consult.

***

Does HRT make you look younger? The verdict by outcome

The answer changes with the outcome. Collagen and thickness improved in small, inconsistent studies. Dryness did not improve significantly when pooled. The two most directly relevant randomized studies found no meaningful treatment effect on facial wrinkles. Hair evidence is thinner still, while symptom relief can make someone look more rested without reversing facial aging.

What you are hoping to notice	What researchers actually measured	Strongest directly relevant evidence	What it found
Fewer facial wrinkles	Investigator and participant ratings at 48 weeks	Randomized, double-blind, double-dummy, placebo-controlled trial; 485 women	No significant treatment-placebo difference[1]
Fewer facial and neck wrinkles	Scores at 11 facial and neck sites, measured yearly	KEEPS ancillary randomized trial; 116 women, four years	No significant hormone-treatment effect[2]
Less facial skin rigidity	Forehead and cheek rigidity	Same four-year KEEPS ancillary trial	No significant hormone-treatment effect[2]
More dermal collagen	Biopsy and collagen measures	2023 meta-analysis; 93 participants across two studies, I²=98%	SMD 2.01, 95% CI 1.42–2.61; large pooled effect on a very small, highly heterogeneous base[3]
Greater skin thickness	Ultrasound or histology	2023 meta-analysis; 141 participants across three studies, I²=95%	SMD 1.27, 95% CI 0.88–1.66; significant, with very high heterogeneity[3]
Greater skin elasticity	Instrument-based elasticity measures	2023 meta-analysis; 251 participants across four studies, I²=76%	SMD 0.28, 95% CI 0.03–0.54; small pooled effect[3]
Less skin dryness	Clinical dryness assessment	2023 meta-analysis; 399 participants across three studies, I²=0%	SMD 0.15, 95% CI −0.05 to 0.35; not significant[3]
More collagen in sun-protected skin	Procollagen and collagen protein in biopsies	Controlled estradiol experiments in older adults	Increased in sun-protected hip skin; not induced in photoaged forearm or facial skin[4]
Fewer crow’s-feet wrinkles	Wrinkle severity, elasticity, procollagen, and MMP-1	Randomized 24-week topical estrone study; 80 postmenopausal women	No added wrinkle or elasticity benefit over vehicle plus sunscreen; MMP-1 expression increased[5]
More lean muscle	DXA-measured lean body mass	Meta-analysis of 12 randomized trials; 4,474 women	0.06 kg difference favoring hormone therapy; not significant, evidence graded low quality[6]
More scalp hair	Hair density or regrowth	The Menopause Society’s 2022 evidence review	Research on whether hormone therapy improves hair density is lacking[7]
Bone-loss prevention	Bone mineral density and fractures	Multiple trials and FDA-approved indications	Established indication; materially stronger evidence than the cosmetic claims[7]

How to read the statistics: SMD means standardized mean difference, an effect size used to combine studies that measured an outcome in different ways. It is not a percentage improvement. I² estimates how much variation across study results reflects between-study heterogeneity rather than sampling error. I²=0% means no heterogeneity was detected; it does not mean the studies were identical. I² of 95% or 98% is very high.

The table contains the central damaging admission: where hormone therapy looks strongest, researchers often measured tissue with a biopsy or instrument. Where researchers measured what women can see in a mirror — facial wrinkling over 48 weeks or four years — the strongest randomized results were negative.

Measured: a change in a tissue property.

Mirror meaning: not necessarily a younger-looking face.

Before you go further: The right online HRT provider is not the same for every woman — it depends on your symptoms, your age and whether you have a uterus, your medication route preference (patch, pill, gel, or vaginal estrogen), your risk history, your insurance or cash-pay situation, and your state. Some situations belong with an in-person clinician first. Because a general answer cannot resolve those for you, use The HRT Index's Find My HRT Path tool to match your situation to the right provider — and to flag when online care is not the right starting point — before your first consult.

***

What does “1,589 patients” in the HRT skin meta-analysis really mean?

The 2023 review included 15 studies and 1,589 participants overall, but no individual appearance outcome used all 1,589. The collagen result came from 93 participants, skin thickness from 141, elasticity from 251, wrinkles from 378, and dryness from 399. The headline denominator is not the denominator behind any one promised result.^[3]

That distinction matters because “15 studies and 1,589 women” sounds like a large, unified anti-aging trial. It was not. The authors pooled different subsets of studies for different outcomes, using different products, routes, body sites, treatment durations, and measurement methods.

Outcome	Studies in that pooled analysis	Participants in that analysis	Heterogeneity	Practical reading
Dermal collagen	2	93	I²=98%	Large pooled effect; very small and very inconsistent base
Skin thickness	3	141	I²=95%	Significant pooled effect; very high inconsistency
Skin elasticity	4	251	I²=76%	Small pooled effect; substantial inconsistency
Wrinkles	2	378	I²=64%	Small pooled effect; two materially different interventions
Skin dryness	3	399	I²=0%	No significant pooled effect

The result with no detected heterogeneity was dryness — and that result was not significant. The results with the most dramatic effect sizes were collagen and thickness — and those carried the highest heterogeneity.

That does not make the review useless. It makes it a map of where the evidence is promising, thin, or structurally unable to answer the mirror question. The authors themselves rated only one included study as low risk of bias across all assessed domains.^[3]

The clean takeaway: do not borrow the total sample size from the whole review to make one outcome sound more certain than it is.

***

Why did the same Yale group get two different answers about wrinkles?

A 2005 observational study of 20 women found fewer wrinkles and less skin rigidity among hormone-therapy users. A later four-year randomized KEEPS study involving overlapping Yale investigators found no significant treatment effect. The designs explain why the randomized result deserves more weight, not why the first group was dishonest.^[8][2]

The 2005 paper compared nine long-term hormone-therapy users with 11 nonusers. The groups were reported as similar in age, race, skin type, smoking, sun exposure, and sunscreen use. The hormone users had lower wrinkle scores and less skin rigidity.^[8]

That finding is interesting. It is also observational. The women had already chosen or been selected for treatment. With nine users and 11 nonusers, the study could not eliminate unmeasured differences between the groups.

The later KEEPS ancillary study solved the core design problem by randomizing recently menopausal women to oral conjugated equine estrogen, transdermal estradiol, or placebo, with progesterone given to women in the active estrogen groups who had a uterus. Investigators followed 116 women for four years and scored 11 face and neck sites. Treatment did not significantly change wrinkle progression or skin rigidity. Skin color was associated with wrinkle scores; randomized hormone assignment was not.^[2]

This is why “estrogen users looked younger” and “estrogen did not reduce wrinkles” can both appear in the literature. The first is an association from a tiny self-selected comparison. The second asks what happened after assignment to treatment or placebo.

Measured: the same broad idea under two different study designs.

Mirror meaning: randomization removed the apparent advantage.

***

Why does the body site change the answer so much?

The clearest estrogen-collagen response came from sun-protected hip skin. In the same research program, two weeks of topical estradiol did not stimulate collagen production in photoaged forearm or facial skin. A separate 24-week facial trial also found no wrinkle or elasticity benefit. Sun damage is not a footnote here; it changes what the result means.^[4][5]

What happened in the hip-versus-face experiments?

Rittié and colleagues studied 70 healthy older volunteers — 40 postmenopausal women and 30 men, mean age about 75. Topical estradiol increased procollagen I and III messenger RNA and collagen protein in sun-protected hip skin after two weeks. The response appeared in women and men.^[4]

The same paper then tested photoaged forearm and facial skin. Two weeks of topical estradiol did not stimulate collagen production at those exposed sites.^[4]

That is not a minor anatomical detail. The strongest mechanistic headline — “estrogen increases collagen” — came from skin that had been protected from decades of ultraviolet exposure.

What happened in the crow’s-feet trial?

Yoon and colleagues randomized 80 postmenopausal women with facial aging to 1% topical estrone or vehicle for 24 weeks. Both groups used sunscreen. The estrogen group did not gain an added improvement in wrinkles or elasticity. Procollagen protein did not increase, while MMP-1 — an enzyme involved in collagen breakdown — rose markedly in sampled skin.^[5]

The authors did not conclude that estrogen is universally bad for skin. They concluded that long-term topical estrogen did not add an anti-aging benefit over vehicle and sunscreen in sun-exposed facial skin and might adversely affect photoaged collagen metabolism.

The strongest collagen response was demonstrated on the hip. In the same experiment, estradiol did not induce collagen in the photoaged face or forearm. A separate facial trial came back negative. Your face is not the body site behind the strongest collagen headline.

This is the missing bridge between mechanism and outcome. “Estrogen receptors exist in skin” is true. “Estrogen can increase collagen under some conditions” is true. Neither sentence proves that systemic menopausal hormone therapy will visibly reverse wrinkles on a sun-exposed face.

***

What is the pooled “wrinkle improvement” actually made of?

The 2023 meta-analysis reported a small pooled wrinkle effect — SMD −0.30 — from two studies and 378 analyzed participants. One was the large systemic trial that found no significant facial-wrinkle benefit. The other was a 1994 topical conjugated-estrogen face-cream study. Pooling them produces a number; it does not make them the same treatment.^[3][1]

Study one: Phillips 2008. The trial enrolled 485 women and assigned them to placebo or one of two low-dose norethindrone acetate/ethinyl estradiol regimens. It was randomized, double-blind, double-dummy, placebo-controlled, and multicenter. Its primary efficacy variables were investigator assessments of coarse and fine facial wrinkling at week 48 and participant assessments of change. It found no significant treatment-placebo improvement in facial wrinkling or sagging.^[1]

Study two: Creidi 1994. Fifty-four postmenopausal women were randomized to conjugated-estrogen cream or vehicle on the face for 24 weeks. The intervention, route, local exposure, era, and question were different from the systemic Phillips trial.^[3][9]

The pooled result is therefore not a clean answer to “Will my patch, gel, or pill make my face look younger?” It is a statistical combination of a large negative systemic trial and a much older topical facial study.

The Phillips trial also used ethinyl estradiol plus norethindrone acetate, not every modern menopausal regimen. That limits how far anyone should generalize it across products. It does not erase the result: it remains the largest trial that made facial wrinkling a primary endpoint.

A May 2026 correction to the Phillips paper addressed a spelling error in Appendix 1. It did not change the methods, endpoints, results, or conclusion.^[10]

***

Where did “you lose 30% of your collagen in five years” come from?

The 30% figure is a widely repeated dermatology estimate, and the American Academy of Dermatology currently publishes it. But the frequently cited 1987 abstract reports collagen and skin-thickness decline of about 1% to 2% per year and does not display a 30%-in-five-years calculation. Treat 30% as a broad estimate from older evidence, not a prediction of your face.^[11][12]

Here is the chain of custody:

1. The patient-facing claim. The American Academy of Dermatology says women’s skin loses about 30% of its collagen during the first five years of menopause, followed by about 2% per year for the next 20 years.^[11]
2. The often-cited original paper. Brincat and colleagues’ 1987 abstract says skin collagen content, skin thickness, and bone mass decline between 1% and 2% per year after menopause.^[12]
3. What is missing from the abstract. It does not show the 30% calculation, the exact five-year derivation, or a facial-photograph outcome.

The honest conclusion is not “30% is false.” The honest conclusion is that a broad educational estimate is often presented with more precision and personal relevance than the visible primary record supports.

Two additional distinctions matter:

• Collagen loss is not the same as visible facial aging. Wrinkles also reflect ultraviolet damage, smoking, facial movement, glycation, skin color, subcutaneous fat, ligaments, muscle, and bone.
• Replacing estrogen does not prove one-for-one restoration. A decline associated with menopause does not mean treatment restores the same percentage, at the same site, in every woman.

Use the number to understand direction and scale. Do not use it as a sales guarantee for a prescription cream or as proof that systemic hormone therapy will take years off your face.

***

What does The Menopause Society actually say about HRT and skin?

The Menopause Society’s 2022 position statement grades the skin claim as Level II. In the same document, prevention of bone loss is supported at Level I. The Society also says research is lacking on whether hormone therapy improves hair density or female-pattern hair loss. That hierarchy supports possible tissue effects without endorsing HRT as a beauty treatment.^[7]

Statement in the same position paper	Evidence level or conclusion
Hormone therapy prevents bone loss	Level I
Estrogen therapy appears to benefit skin thickness, elasticity, and collagen when given at menopause	Level II
Hair density and female-pattern hair loss worsen after menopause, but research is lacking on whether hormone therapy helps	Research lacking

The skin grade is Level II. It is not the weakest evidence tier. It still does not establish predictable facial rejuvenation, because the statement concerns measured skin properties rather than a reliable visible outcome in the mirror.

The Society’s 2024 misinformation statement goes further on the decision itself: estrogen-containing hormone therapy is not recommended to prevent aging or to manage primarily age-related changes in skin, hair, or weight.^[13]

Measured: a professional society’s graded reading of skin-property evidence.

Mirror meaning: the organization most associated with evidence-based menopause care does not tell women to start hormone therapy for a younger-looking face.

If this evidence made you realize appearance is not the real problem — the real problem is sleep, hot flashes, painful sex, mood disruption, or another symptom you have been carrying — that is a different and more legitimate decision.

Map your symptoms, risk history, insurance, and state before choosing a clinic →

The HRT Index's Find My HRT Path tool also flags when online care is not the right starting point.

***

Does HRT help hair grow back?

Hair loss was the most distressing menopause-related appearance change in a 2,090-woman French survey, ranking above wrinkle deepening. But distress is not treatment evidence. The Menopause Society says research is lacking on whether hormone therapy improves hair density, and a 2025 systematic review found associations between menopause and several forms of alopecia rather than proof that HRT reverses them.^[14][15][7]

The survey came from a nationally representative sample of 15,050 French adults and analyzed 2,090 postmenopausal women aged 45 to 65. Among women affected by each change, the most disturbing were:^[14]

Rank	Change	Women identifying it as most disturbing
1	Hair loss	31.1%
2	Excessive sweating	26.9%
3	Skin dryness	21.4%
4	Unwanted hair growth	20.8%
5	Wrinkle deepening	19.5%

The study was funded by Vichy Laboratoires, which sells products to this population. That does not erase the finding. It belongs next to it.

A systematic review published online in December 2025 evaluated 40 studies of menopause or menopausal hormone therapy in relation to common dermatologic conditions. Alopecia — especially frontal fibrosing alopecia and female-pattern hair loss — had the strongest postmenopausal associations, while the authors emphasized major evidence gaps.^[15]

Three practical points matter more than an anti-aging promise:

1. Topical minoxidil is the best-established first-line treatment for female-pattern hair loss. The American Academy of Dermatology identifies it as the most-recommended treatment and the only FDA-approved treatment for female-pattern hair loss.^[16]
2. Hair loss is not automatically menopause. Pattern hair loss, telogen effluvium, thyroid disease, iron deficiency, medication effects, scarring alopecia, and other causes can look similar at first. The workup should follow the pattern and history rather than assume estrogen deficiency.
3. Testosterone is not a cosmetic shortcut. The global consensus statement supports testosterone therapy for postmenopausal women only for hypoactive sexual desire disorder after a formal assessment. Physiologic-dose trials did not show alopecia as a significant adverse effect, although mild acne and body or facial hair growth can occur.^[17]

That third point corrects a common overstatement. It is too strong to tell every genetically susceptible woman that prescribed testosterone will predictably raise follicular DHT and worsen scalp thinning. The evidence does not support that certainty. It is still reasonable to discuss new hair shedding, acne, or unwanted hair with the prescriber.

In the United States, testosterone is a Schedule III controlled substance. It requires a prescription and lawful clinician oversight. There is no FDA-approved testosterone product specifically indicated for women’s menopausal symptoms.^[18]

Measured: menopause is associated with hair changes, and women find them deeply distressing.

Mirror meaning: do not let a hormone marketing page replace a hair-loss diagnosis.

***

Does HRT change body shape or help with weight loss?

Hormone therapy is not a weight-loss treatment. A meta-analysis of 12 randomized trials involving 4,474 women found a 0.06 kg difference in lean-body-mass change favoring therapy — about two ounces — which was not statistically significant. A separate two-year trial found no treatment-placebo difference in weight, total fat, abdominal fat, or fat-free mass.^[6][19]

The 4,474-woman analysis is the cleanest answer to whether menopausal hormone therapy preserves lean mass. The median treatment duration was two years. The pooled mean difference was 0.06 kg, with a 95% confidence interval from −0.05 to 0.18 kg and p=0.26. The authors graded the evidence low quality and concluded that other interventions should be explored for muscle preservation.^[6]

A smaller randomized, double-blind, placebo-controlled trial assigned 76 early postmenopausal women to conjugated estrogens plus medroxyprogesterone acetate or placebo. Fifty-one completed and were analyzed. Over two years, the groups did not differ in intra-abdominal fat, subcutaneous abdominal fat, total fat, percent fat, fat-free mass, or weight.^[19]

That trial also found a 17% reduction in insulin sensitivity in the active-treatment group that persisted at two years and reversed after treatment stopped. It does not prove that every modern estrogen route or formulation worsens insulin sensitivity; it describes one oral conjugated-estrogen/medroxyprogesterone regimen in one small study. It is included because it prevents a false one-way story in which every metabolic effect is automatically beneficial.^[19]

Do not stack isolated strength, abdominal-fat, and insulin-sensitivity estimates from different reviews as though they answer one question. They come from different populations, formulations, comparators, and endpoints.

What can be said without overselling it:

• Menopause is associated with changes in fat distribution and body composition.
• A 2026 clinical review concluded that menopausal hormone therapy may attenuate central fat accumulation but is not indicated as a primary weight-loss intervention.^[20]
• Randomized evidence does not establish hormone therapy as a reliable way to lose weight or preserve a visibly meaningful amount of muscle.
• If treatment improves sleep, energy, joint symptoms, or hot flashes, it may make exercise and meal planning easier. That is an indirect route, not a drug-induced weight-loss effect.

Measured: at most, small or inconsistent shifts in body composition.

Mirror meaning: your waistband may change for many reasons. Do not start hormone therapy expecting the scale to move.

***

What appearance-related side effects are listed on estrogen labels?

Current estradiol labeling lists several appearance-related adverse reactions, including chloasma or melasma that may persist after discontinuation, loss of scalp hair, hirsutism, pruritus, and rash. These are possible reported reactions, not predictions and not frequency estimates. The label for the exact product prescribed to you controls.^[21]

Nobody puts these in the hero image. They are in the regulatory document anyway.

Melasma or chloasma

Some estradiol labels state that chloasma or melasma may occur and may persist after the drug is discontinued. That matters before treatment, especially for someone with a history of pigmentation changes during pregnancy or while using hormonal contraception.^[21]

Scalp-hair loss and hirsutism

The same dermatologic adverse-reaction sections can list loss of scalp hair and hirsutism. The fact that both shedding and unwanted hair growth can appear in labeling is another reason not to promise a simple “estrogen makes hair younger” effect.^[21]

Itching and rash

Pruritus and multiple rash types also appear. Different estrogen products and routes have different excipients, application sites, and label language, so a class-level summary cannot replace the package insert for the product in hand.

Being fair about the label: an adverse-reaction list may combine events observed in trials with postmarketing reports. It does not tell you that an event is common, that estrogen caused every report, or that most users will experience it. But a page that lists only hoped-for appearance benefits and none of the labeled appearance risks is not helping you decide. It is selling you a mood.

***

Is it too late to start HRT if you are past the “window”?

There is no proven cosmetic window to miss. FDA’s February 2026 request directed systemic-product labels to add consideration of initiation before age 60 or within 10 years of menopause onset for moderate-to-severe vasomotor symptoms. As of September 3, 2026, FDA’s live page listed six products with updated prescribing information across systemic, local vaginal, and progestogen categories.^[22]

The timing discussion is real. It is also often dragged into claims it does not prove.

The six products on FDA’s live updated-information page were Prometrium, Divigel, Cenestin, Enjuvia, Estring, and Bijuva. That list included different product categories and did not mean every menopausal hormone product already carried identical revised wording.^[22]

The timing language concerns vasomotor-symptom treatment. It does not create an anti-aging indication.

For appearance, the KEEPS result is the useful reality check. Its participants were recently menopausal — within three years of their final menstrual period — and were followed for four years. That is close to the best-case timing story. The randomized treatment groups still did not develop a significant wrinkle or skin-rigidity advantage over placebo.^[2]

So if you are worried you missed a cosmetic window, let that fear go. There is no strong evidence that starting at 52 would have preserved a younger face that starting later could not. Timing matters because the balance of symptom benefits and health risks changes with age, years since menopause, route, dose, and medical history. That is a clinical decision, not a beauty deadline.

***

How long would HRT take to change your skin?

There is no reliable cosmetic timeline because there is no reliable facial-wrinkle effect to time. Objective studies measured outcomes after two weeks, 24 weeks, 48 weeks, and four years. Tissue markers changed at some protected sites; the major facial trials remained negative. Symptom relief can make someone look more rested sooner without altering dermal aging.

Change	When it was measured	What happened
Procollagen in sun-protected hip skin	Two weeks	Increased after topical estradiol[4]
Procollagen in photoaged forearm and facial skin	Two weeks	Not induced[4]
Crow’s-feet wrinkles and elasticity	24 weeks	No added benefit over vehicle plus sunscreen[5]
Facial wrinkling and sagging	48 weeks	No significant treatment-placebo benefit[1]
Facial and neck wrinkles; skin rigidity	Annually for four years	No significant treatment effect[2]
Skin dryness	Pooled across three studies	No significant pooled benefit[3]

The change many women notice first is not collagen. It is relief.

The Menopause Society describes hormone therapy as the most effective treatment for vasomotor symptoms, with trials showing roughly a 75% reduction in their frequency and substantial reduction in severity.^[7] If someone stops waking drenched at 3 a.m., she may look less exhausted, feel more animated, and carry herself differently within weeks. That is real. It is also a sleep-and-symptom effect, not proof of facial rejuvenation.

A page should not promise that every woman will “look visibly different in eight weeks.” Trials did not establish that outcome. The honest permission is simpler: if sleep improves, you may notice your face looks less tired before any instrument could detect a skin-property change.

A baseline that is actually useful

If appearance is one of your secondary goals, take a baseline photo before treatment:

• same room and time of day;
• same window or artificial light;
• same camera, distance, and angle;
• no makeup or filter;
• neutral expression;
• no new facial procedure or skincare active during the comparison period unless you record it.

Most commercial before-and-after images do not control those variables. Lighting, makeup, focal length, facial expression, hydration, sleep, and weight change can produce a bigger visible difference than the treatment being sold.

***

Does the type of HRT matter for skin — patch, pill, gel, or vaginal estrogen?

Route matters for absorption, symptoms, convenience, and risk; it has not been proven to rank cosmetic benefit. The Menopause Society says transdermal routes and lower doses may decrease venous-thromboembolism and stroke risk, but comparative randomized trial data are lacking. Anyone ranking patch, pill, and gel by wrinkle benefit is extrapolating.^[7]

Patch, gel, or spray versus oral estrogen

Transdermal estradiol avoids first-pass hepatic metabolism. Observational evidence and biologic plausibility support a lower clot risk than oral estrogen for some women, and the Society says transdermal routes may decrease venous-thromboembolism and stroke risk. “May” is the accurate word because head-to-head randomized outcome trials are lacking.^[7]

That is a safety consideration. It is not evidence that a patch makes the face look younger than a pill.

Estrogen with or without endometrial protection

A woman with an intact uterus who uses systemic estrogen ordinarily needs adequate endometrial protection with a progestogen or another appropriate regimen. Unopposed systemic estrogen increases endometrial-hyperplasia and cancer risk. This rule does not automatically extend to every low-dose local vaginal-estrogen regimen; route and dose matter.^[7]

That is why a treatment comparison should never treat “estrogen” as one interchangeable thing. The molecule, dose, route, uterus status, symptoms, and risk history all matter.

Low-dose vaginal estrogen

Low-dose vaginal estrogen is intended for genitourinary syndrome of menopause — vaginal dryness, painful sex, and related urinary symptoms. Systemic absorption is generally low at recommended low doses but varies by product and dose. It is not a facial treatment and should not be repurposed for the face without explicit product-specific prescribing instructions.^[7]

***

Can you put estrogen cream on your face?

Do not repurpose vaginal estrogen cream for facial use unless the prescriber gives product-specific directions. Prescription facial estriol creams are a separate compounded category. They are not FDA-approved products, and FDA says no drug containing estriol has been approved. A compounded estriol formula must never be blurred with FDA-approved estradiol or tretinoin products.^[23]

Three categories are routinely collapsed online:

1. FDA-approved vaginal estrogen products are labeled for vulvovaginal or genitourinary symptoms, not facial aging.
2. FDA-approved systemic menopausal hormone products are labeled for specific menopause-related indications, not facial rejuvenation.
3. Compounded prescription facial creams containing estriol are individualized preparations that FDA has not reviewed for safety, effectiveness, manufacturing quality, or an anti-aging indication before marketing.

The word “prescription” does not make those categories equivalent. A licensed prescriber can prescribe an FDA-approved drug off-label and can order a compounded preparation when clinically appropriate. That does not turn the off-label use or compounded finished product into an FDA-approved treatment.^[23]

Why the vaginal tube is not a facial dosing tool

A vaginal cream’s concentration, vehicle, applicator, labeled amount, absorption data, and tissue target were developed for vaginal use. Facial skin has a different barrier and exposure pattern. Without product-specific directions, you do not know whether the amount placed on the face resembles any studied dose or what systemic exposure it produces.

“Low systemic absorption” is not permission to improvise. It is a product-, dose-, and route-specific pharmacokinetic claim.

What about prescription estriol face cream?

That is a real prescription category sold by several telehealth companies and compounding pharmacies. It is also a category where marketing frequently outruns the evidence. Small studies of topical estrogens have reported changes in skin thickness, hydration, elasticity, or collagen, but products, body sites, estrogen types, doses, and methods vary. The negative facial trials still belong in the decision.^[24]

The question is not whether a clinician can prescribe it. The question is whether the exact finished formula being sold has evidence strong enough for the promise attached to it.

***

What works better when looking younger is the actual goal?

For photoaged facial skin, daily broad-spectrum sun protection and topical retinoids have a clearer evidence and regulatory trail than menopausal hormone therapy. FDA-approved Renova 0.02% tretinoin is labeled as an adjunct for mitigating fine facial wrinkles within a comprehensive skin-care and sun-avoidance program. It is not labeled to erase wrinkles or restore youth.^[25]

That distinction is useful because it shows what an honest cosmetic label looks like.

Renova’s prescribing information says it should be used with comprehensive skin care and sun avoidance. Across five vehicle-controlled trials, two showed significant improvement in fine wrinkling and three did not. The label also says the product does not eliminate wrinkles, repair sun-damaged skin, reverse photoaging, or restore younger skin.^[25]

That is not a miracle claim. It is a bounded indication with negative trials still visible.

A decision ladder that starts with the strongest fit

1. Daily broad-spectrum sunscreen and sun-protective behavior. This addresses the ultraviolet exposure that helps explain why protected hip skin and photoaged facial skin did not respond the same way.^[25]
2. A retinoid discussion if fine photoaging is the target. Tretinoin has an FDA-reviewed facial-wrinkle indication in at least one product, with explicit limits.
3. A dermatologist when the problem is pigmentation, scarring, rapid hair loss, a new lesion, or a condition rather than ordinary aging. The diagnosis changes the treatment.
4. Menopause care when symptoms are the real driver. Treat hot flashes, night sweats, painful sex, sleep disruption, or another clinical problem on its own evidence.
5. A compounded estriol face-cream discussion only after the approval status, evidence gap, formula, price, refill terms, and alternatives are clear.

Do not trust a generic-tretinoin cash-price number unless it names the strength, tube size, pharmacy, and verification date. Pharmacy prices can vary substantially. The reliable decision fact here is the regulatory and evidence distinction, not a floating discount-card number.

***

Is Winona’s estriol face cream FDA-approved?

No. Winona’s finished Estriol Face Cream with Tretinoin is compounded and is not FDA-approved. Winona’s public product page says its “active ingredients” are FDA approved, but FDA says no drug containing estriol has been approved. Tretinoin has FDA-approved products; estriol does not. That difference must be visible before anyone clicks.^[26][23]

Provider-stated versus independently verified — September 3, 2026

Decision fact	Provider-stated	What we verified
Product	Estriol Face Cream with Tretinoin	A prescription compounded finished product; not FDA-approved
Price	$150 per three-month supply	Confirmed on the public product page September 3, 2026[26]
Active ingredients displayed	Estriol and tretinoin	Confirmed; the public product page did not display the strengths checked September 3, 2026[26]
Approval wording	“The active ingredients … estriol and tretinoin, are FDA approved”	Inaccurate as written: FDA states that no FDA-approved drugs contain estriol. FDA approval of some tretinoin products does not approve this compounded combination[23]
Evidence wording	Product page calls the cream “clinically proven” and promises multiple visible benefits	The public page did not identify a randomized controlled trial of the finished Winona formula in the claim block we reviewed[26]
Refill cadence	Three-month supply	Winona’s FAQ says 90-day prescriptions are processed every 84 days unless paused or canceled[27]
Cancellation and refund	Subscription can be canceled	A full refund is available only within the 24-hour processing window; after that, orders cannot be canceled, refunded, or returned[27]
Insurance	Winona does not bill insurance directly	Confirmed; the product page says HSA/FSA may be used and documents may be submitted for possible reimbursement[26]

The page says systemic effects are expected to be “almost certainly minimal” and calls the recommended estriol amounts safe for long-term use. Those remain strong statements for an individualized compounded formula without an FDA-reviewed finished-product label. They should be discussed with the prescriber rather than treated as settled facts.^[26]

This is the damaging admission that belongs next to the affiliate link: Winona offers a convenient prescription process and transparent three-month price, but the exact public formula strength was not visible, the refill cycle is shorter than 90 calendar days, the refund window is narrow, and its FDA-approval wording is wrong about estriol.

Read our full Winona estriol face cream review before paying →

Sponsored/affiliate link. We may earn a commission if you purchase through our review. The approval findings above do not change with commission.

***

Should you take menopausal hormone therapy just to look younger?

No. Do not start systemic menopausal hormone therapy solely to make your face look younger. FDA does not approve menopausal hormone therapy for facial aging, hair regrowth, or weight loss, and The Menopause Society says estrogen-containing therapy is not recommended to prevent aging or manage primarily age-related skin, hair, or weight changes.^[28][13]

That answer does not require anyone to pretend hormone therapy is bad.

Menopausal hormone therapy is the most effective treatment for bothersome vasomotor symptoms. It also prevents bone loss and fracture, and local vaginal estrogen is highly effective for genitourinary syndrome of menopause when over-the-counter approaches are not enough.^[7]

Those are real reasons. “I want my face to look younger” is not one of the established indications.

A 2026 perspective in Life argued that hormone therapy’s possible skin effects could have aesthetic relevance. The paper also acknowledged that hormone therapy is not approved as a cosmetic treatment and that aesthetic prescribing creates a higher ethical burden because the medical necessity is lower.^[29]

The paper is a perspective, not a clinical guideline or randomized facial-outcome trial. One author was employed by Dermatology Consulting Services, and that firm conducted an industry-sponsored topical estriol study discussed in the paper. The paper declared no conflicts of interest; the employment and study sponsorship still belong in the reader’s view of the argument.^[29]

Here is the decision line:

• Symptoms are disrupting your life, and appearance is a secondary hope: a menopause consultation may be reasonable.
• Appearance is the only reason: start with evidence-based dermatologic care, not systemic hormone therapy.
• A clinic guarantees cosmetic improvement before reviewing your history: leave.

Permission does not require a beauty claim. You are allowed to seek treatment because hot flashes are wrecking your work, because sleep has disappeared, because sex hurts, because your mood feels unfamiliar, or because symptoms are affecting your relationships. Those reasons stand on their own.

***

Who needs a clinician-led evaluation before systemic HRT?

Systemic hormone therapy should not be started from a cosmetic sales funnel. Unexplained vaginal bleeding, prior estrogen-sensitive cancer, coronary disease, stroke, heart attack, venous thromboembolism, serious liver disease, or a high inherited clot risk can materially change the decision. Local vaginal treatment and nonhormonal options require their own separate assessment.^[7]

For oral or transdermal systemic therapy, The Menopause Society lists contraindications that include unexplained vaginal bleeding, liver disease, prior estrogen-sensitive cancer, prior coronary heart disease, stroke, myocardial infarction, venous thromboembolism, and a personal history or inherited high risk of thromboembolic disease.^[7]

That does not mean every woman with a complicated history has no menopause treatment options. It means the route, dose, indication, alternatives, and specialty involvement matter too much for an appearance-first checkout.

Start in person or with the relevant specialist when:

• you have unexplained or postmenopausal bleeding;
• you have a history of breast, endometrial, or another estrogen-sensitive cancer;
• you have had a clot, stroke, heart attack, or established coronary disease;
• you have serious liver disease or a known high-risk clotting disorder;
• a new breast mass, rapidly changing skin lesion, scarring hair-loss pattern, or other finding needs a physical examination;
• the symptoms could represent an urgent condition;
• online care cannot obtain the exam, imaging, pathology, or coordinated specialty input the decision requires.

Age 60 or more than 10 years since menopause is not an automatic universal ban. It changes the benefit-risk calculation, which is why the decision needs to be individualized rather than sold as a rejuvenation package.^[7]

***

What should a good menopause consultation include?

A legitimate consult starts with symptoms, menstrual and surgical history, uterus status, bleeding, cancer and clot history, cardiovascular and liver risk, current medicines, pregnancy possibility when relevant, and your preferences. It may end with hormone therapy, a nonhormonal option, local treatment, testing, referral, or no prescription. A prescription is not proof that the visit was better.

The honest limitation you should hear first

Midi is not a beauty clinic. Its public menopause pathway is built around symptoms and health goals, and booking does not guarantee hormone therapy. A clinician may recommend an FDA-approved hormone product, a nonhormonal treatment, lifestyle support, targeted testing, another specialist, or no prescription. If appearance is the only reason and there is no clinical indication, paying for a visit and leaving without HRT is a correct possible outcome.^[30]

That is not a weakness. It is the safeguard.

A useful first visit should resolve these questions:

1. What symptom or diagnosis is treatment targeting?
2. Is systemic treatment needed, or would local or nonhormonal care fit better?
3. Do you have a uterus, and what endometrial protection is required if systemic estrogen is prescribed?
4. Which route best fits your risk profile, symptoms, cost, and preferences?
5. Are labs clinically useful for ruling out another cause or monitoring a treatment — rather than being sold as a universal “hormone optimization” package?
6. What side effects, bleeding changes, or warning signs require contact or urgent care?
7. What will the visit, medication, laboratory work, and follow-up cost separately?
8. How do you cancel, pause, or change care?

Online menopause options — provider-stated facts verified September 3, 2026

Provider	Best fit in this context	Current published price	Insurance and labs	Access and medication notes
Midi Health	Full video-based menopause evaluation; insurance users; women who want a broad symptom and risk review	$250 first self-pay visit; $150 return visit	In-network with most major PPO plans; plan-specific copays, deductibles, and coinsurance apply. Labs and prescriptions may add separate costs	Available in all 50 states. Care plans may include FDA-approved hormone therapy, nonhormonal treatment, testing, or referral. Medicare is out of network; Medicaid and Medi-Cal patients are not accepted[30]
Sesame	Cash-pay subscription with video visits, messaging, and provider choice	$59/month; medication cost not included	Does not bill insurance for the subscription. Basic listed labs are included if ordered, but patients in NY, NJ, RI, and ND may owe the lab directly under stated exceptions	Prescription options vary by clinician and eligibility. Cancel at least three hours before the initial visit for a first-month refund; after the visit, that month is nonrefundable[31]
Hers	Cash-pay, fully online medication pathway for eligible patients who value published package pricing	Oral plans from $79/month; patch plans from $134/month with a 12-month plan	Does not require insurance; provider access is included in the plan description	Offers oral or transdermal estradiol and progesterone for eligible customers. Availability and eligibility are confirmed during intake; published “from” prices depend on the plan term[32]

These are not interchangeable products. Midi’s price is a visit price. Sesame’s is a care subscription before medication. Hers publishes bundled plan prices tied to plan length. Comparing only the smallest monthly number would be fake “starting at” math.

Does the symptom-first model sound like your situation? Check Midi’s state and insurance eligibility before booking →

Sponsored/affiliate link. We may earn a commission if you book. Verify your exact plan, state, patient responsibility, prescription cost, and lab cost during registration.

On testimonials — and why there is no “ten years younger” quote here

We did not use a testimonial as evidence that hormone therapy visibly changed someone’s face. A personal account cannot isolate hormone therapy from lighting, makeup, camera, weight, sleep, skincare, procedures, and time.

Company before-and-afters and creator testimonials can describe a person’s experience. They cannot replace a randomized trial, and they should not be repackaged as proof that an unapproved cosmetic use works.

We will not publish a quote saying hormone therapy took ten years off someone’s face. The strongest facial randomized evidence did not establish that effect, and no menopausal hormone product is approved to make that promise.

***

What did we verify for this page?

Every study statistic, regulatory claim, provider price, lab-inclusion statement, refill term, and cancellation term retained on this page was checked against the cited primary paper, regulator, professional-society document, or provider page. The verification date is September 3, 2026. Commercial terms can change after that date, so checkout remains the final source for your exact cost.

Research and regulatory checks

• We read the 2023 systematic review and meta-analysis outcome by outcome, including the per-outcome participant counts, effect sizes, confidence intervals, p values, and I² values.^[3]
• We checked the 485-woman Phillips trial design, arm sizes, primary facial endpoints, and null result. We also checked the 2026 correction; it fixes a spelling error in Appendix 1 and does not alter the trial results.^[1][10]
• We checked the KEEPS skin ancillary trial sample, randomized treatments, four-year follow-up, 11 face-and-neck sites, and null treatment effect.^[2]
• We checked the Rittié hip-versus-photoaged-site experiment and confirmed the two-week treatment duration.^[4]
• We checked the Yoon facial trial’s 80-woman sample, 24-week duration, vehicle-plus-sunscreen comparison, and MMP-1 finding.^[5]
• We confirmed The Menopause Society’s Level II skin statement and retained the Level I bone comparison.^[7]
• We separated FDA’s system-wide February 2026 labeling request from the first six products whose revised prescribing information appeared on FDA’s live list.^[22]
• We checked current FDA language on estriol and compounded hormone products, the Renova label, current estradiol adverse-reaction labeling, and testosterone’s Schedule III status.^{[23][25][21][18]}

Provider and commercial checks

• Midi Health: $250 first self-pay visit, $150 return visit, all-50-state availability, PPO plan dependence, Medicare out-of-network status, and no Medicaid or Medi-Cal patients.^[30]
• Sesame: $59 monthly menopause subscription, basic included labs when ordered with state exceptions, medication charged separately, no insurance billing for the subscription, and stated refund terms.^[31]
• Hers: oral plans from $79 per month and patch plans from $134 per month with a 12-month plan; eligibility and exact plan confirmed during intake.^[32]
• Winona: $150 three-month face-cream price, 84-day refill processing for a 90-day supply, 24-hour refund window, ingredient wording, public absence of formula strengths, and compounded status.^[26][27]

What we did not turn into a claim

• We did not publish an unverified generic-tretinoin cash price.
• We did not keep isolated 5%, 6.8%, or other review-level body-composition figures that could not be presented as one coherent outcome.
• We did not say a testosterone prescription predictably causes scalp-hair loss in women; the consensus evidence does not support that certainty.
• We did not claim all menopausal hormone products already carry identical February 2026 labeling.
• We did not call a compounded estriol product FDA-approved, equivalent to an FDA-approved product, or clinically proven.
• We did not invent a clinician review, author credential, testimonial, before-and-after, or provider score.

This page is editorial research. It is not medically reviewed by a clinician, and it does not pretend to predict what any drug will do to one person’s face.

***

Frequently asked questions

Does HRT reverse skin aging?

No. Menopausal hormone therapy can alter some measured skin properties, but the randomized trials reviewed here do not show that it reverses skin aging as a whole. The strongest collagen findings came from small studies and sun-protected body sites. The largest facial trial and the four-year KEEPS study found no significant wrinkle benefit.^[1][2][4]

Does HRT get rid of wrinkles?

The best directly relevant randomized evidence says not reliably. A 485-woman, 48-week placebo-controlled trial found no significant improvement in facial wrinkling or sagging. A 116-woman randomized study followed for four years also found no treatment effect on face-and-neck wrinkles or skin rigidity.^[1][2]

How long does HRT take to improve skin?

There is no reliable facial timeline because there is no reliable facial-wrinkle outcome. Studies measured protected-skin collagen after two weeks, crow’s feet after 24 weeks, facial wrinkling after 48 weeks, and face-and-neck wrinkles over four years. The facial trials did not establish a benefit.^[4][5][1][2]

Does HRT help hair grow back?

There is no established trial-grade answer showing menopausal hormone therapy regrows scalp hair. The Menopause Society says research on hormone therapy and hair density is lacking. Female-pattern hair loss has other evidence-based treatments, and the American Academy of Dermatology identifies topical minoxidil as the most-recommended and only FDA-approved treatment for that condition.^[7][16]

Can HRT be prescribed just for skin?

A prescriber can make an individualized off-label decision, but facial aging is not an FDA-approved indication for menopausal hormone therapy. The Menopause Society says estrogen-containing therapy is not recommended to prevent aging or manage primarily age-related skin, hair, or weight changes. A responsible clinic should not guarantee a prescription or cosmetic result.^[13][28]

Does HRT make you gain weight?

Randomized evidence does not show a meaningful lean-mass benefit and does not support hormone therapy as a weight-loss treatment. A 4,474-woman randomized-trial meta-analysis found a nonsignificant 0.06 kg difference in lean-mass change. A separate two-year trial found no difference in weight or measured body-fat compartments between treatment and placebo.^[6][19]

Is it too late to start HRT at 60?

For appearance, there is no proven cosmetic window. For symptoms and health risks, age and years since menopause matter. FDA has directed systemic-product labels to add consideration of starting for moderate-to-severe vasomotor symptoms before age 60 or within 10 years of menopause onset. That is not an automatic rule and not a facial-aging indication.^[22]

Does HRT help facial sagging or volume loss?

No trial in this evidence set established predictable restoration of facial sagging or volume. The Phillips trial assessed sagging as a secondary outcome and found no significant benefit. Facial volume also reflects fat compartments, ligaments, muscle, and bone — not just dermal collagen.^[1]

Can vaginal estrogen cream be used on the face?

Not without product-specific directions from the prescriber. Vaginal estrogen products are formulated, dosed, and labeled for vaginal or genitourinary tissue. Facial use is off-label, and a vaginal prescription should not be treated as interchangeable with a separately compounded facial formula.^[7][23]

Does the type of HRT matter for skin — patch, pill, or gel?

The evidence reviewed here does not establish a cosmetic winner among patch, pill, or gel. Route matters for absorption, symptoms, preferences, and risk. The Menopause Society says transdermal routes and lower doses may reduce venous-thromboembolism and stroke risk, while noting that comparative randomized trial data are lacking.^[7]

Will skin changes reverse after stopping HRT?

The trials do not provide a dependable answer for facial appearance. Effects that depend on active treatment may diminish after stopping, but that should not be converted into a guaranteed timeline. A current estradiol label also states that melasma or chloasma may persist after discontinuation.^[21]

Does testosterone make women look younger?

There is no good evidence supporting testosterone as an appearance treatment for women. The global consensus statement recognizes one evidence-based indication: hypoactive sexual desire disorder in postmenopausal women after formal assessment. In the United States, testosterone is a Schedule III controlled substance and requires a prescription and lawful clinician oversight.^[17][18]

***

The bottom line

Hormone therapy does measurable things to skin tissue. The strongest collagen response was demonstrated where the sun had not reached. When researchers measured the thing most women asking this question actually care about — facial wrinkles, over 48 weeks or four years, against placebo — they did not find a significant treatment benefit.

That is not a reason to avoid menopausal hormone therapy when you have an evidence-based reason to use it. It is the most effective treatment for bothersome hot flashes and night sweats, it prevents bone loss and fracture, and local vaginal treatment can be highly effective for genitourinary symptoms.^[7]

If hot flashes stop breaking your sleep, you may look and feel dramatically better. That is a valid outcome. It is just not proof that the drug reversed facial aging.

Start hormone therapy for the symptoms and health indication you are actually treating — not because somebody sold you your own face back.

Use the about-90-second Find My HRT Path tool →

It asks about symptoms, history, insurance, and state, then flags when online care is not the right starting point.

***

Affiliate disclosure: The HRT Index may earn a commission from some provider links on this page. Provider evaluations follow The HRT Index Verification Standard across clinical legitimacy, care quality, medication fit, price transparency, and access. Commission does not change the facts reported here. This page is educational and is not medical advice.

Sources

¹ Phillips TJ, et al. “Does Hormone Therapy Improve Age-Related Skin Changes in Postmenopausal Women? A Randomized, Double-Blind, Double-Dummy, Placebo-Controlled Multicenter Study.” Journal of the American Academy of Dermatology (2008). PubMed.

² Owen L, et al. “Effects of Hormones on Skin Wrinkles and Rigidity Vary by Race/Ethnicity: Four-Year Follow-Up from the Ancillary Skin Study of the Kronos Early Estrogen Prevention Study.” Fertility and Sterility (2016). PubMed.

³ Pivazyan L, et al. “Skin Rejuvenation in Women Using Menopausal Hormone Therapy: A Systematic Review and Meta-Analysis.” Journal of Menopausal Medicine (2023). Full text at PubMed Central.

⁴ Rittié L, et al. “Induction of Collagen by Estradiol: Difference Between Sun-Protected and Photodamaged Human Skin In Vivo.” Archives of Dermatology (2008). PubMed.

⁵ Yoon HS, et al. “Long-Term Topical Oestrogen Treatment of Sun-Exposed Facial Skin in Post-Menopausal Women Does Not Improve Facial Wrinkles or Skin Elasticity, but Induces Matrix Metalloproteinase-1 Expression.” Acta Dermato-Venereologica (2014). PubMed.

⁶ Javed AA, et al. “Association Between Hormone Therapy and Muscle Mass in Postmenopausal Women: A Systematic Review and Meta-analysis.” JAMA Network Open (2019). Full text at PubMed Central.

⁷ The North American Menopause Society. “The 2022 Hormone Therapy Position Statement of The North American Menopause Society.” Menopause (2022). DOI record.

⁸ Wolff EF, Narayan D, Taylor HS. “Long-Term Effects of Hormone Therapy on Skin Rigidity and Wrinkles.” Fertility and Sterility (2005). PubMed.

⁹ Creidi P, et al. “Effect of a Conjugated Oestrogen (Premarin) Cream on Ageing Facial Skin: A Comparative Study with a Placebo Cream.” Maturitas (1994). PubMed.

¹⁰ “Correction to ‘Does Hormone Therapy Improve Age-Related Skin Changes in Postmenopausal Women?’” Journal of the American Academy of Dermatology (2026). PubMed.

¹¹ American Academy of Dermatology. “Caring for Your Skin in Menopause.” AAD patient guidance.

¹² Brincat M, et al. “Skin Collagen Changes in Post-Menopausal Women Receiving Different Regimens of Estrogen Therapy.” Obstetrics & Gynecology (1987). PubMed.

¹³ The Menopause Society. “Misinformation Surrounding Hormone Therapy.” (2024). Official statement.

¹⁴ Foulc P, et al. “Skin, Hair and Beyond: The Impact of Menopause.” Journal of the European Academy of Dermatology and Venereology (2024). DOI record.

¹⁵ Roster K, et al. “Menopause and Common Dermatoses: A Systematic Review.” American Journal of Clinical Dermatology (published online 2025). PubMed.

¹⁶ American Academy of Dermatology. “Thinning Hair and Hair Loss: Could It Be Female Pattern Hair Loss?” AAD patient guidance.

¹⁷ Davis SR, et al. “Global Consensus Position Statement on the Use of Testosterone Therapy for Women.” (2019). Full text at PubMed Central.

¹⁸ Electronic Code of Federal Regulations. “21 CFR §1308.13 — Schedule III.” Current eCFR.

¹⁹ Sites CK, et al. “The Effect of Hormone Replacement Therapy on Body Composition, Body Fat Distribution, and Insulin Sensitivity in Menopausal Women: A Randomized, Double-Blind, Placebo-Controlled Trial.” Journal of Clinical Endocrinology & Metabolism (2005). PubMed.

²⁰ Younglove C, et al. “Clinical Review: Menopause Hormone Therapy in Weight Management.” (2026). PubMed.

²¹ DailyMed. “Estradiol Tablets, USP — current prescribing information.” Official label.

²² U.S. Food and Drug Administration. February 2026 labeling-change request and live list of menopausal hormone therapies with updated prescribing information.

²³ U.S. Food and Drug Administration. “Menopause.” FDA states that it has not approved any drugs containing estriol and explains that compounded drugs are not FDA-approved. FDA women’s health page.

²⁴ Rzepecki AK, et al. “Estrogen-Deficient Skin: The Role of Topical Therapy.” (2019). Full text at PubMed Central.

²⁵ DailyMed. “RENOVA — tretinoin cream, 0.02%, prescribing information.” Official label.

²⁶ Winona. “Estriol Cream with Tretinoin (Rx).” Price and public claims checked September 3, 2026. Provider product page.

²⁷ Winona. “Frequently Asked Questions.” Billing, refill, cancellation, refund, and pharmacy statements checked September 3, 2026. Provider FAQ.

²⁸ U.S. Food and Drug Administration. “Menopause.” FDA women’s health page.

²⁹ Lephart ED, Draelos ZD. “Overview of Aging, Skin Health, Estrogen, Menopause and Hormone Replacement Therapy.” Life (2026). Full text at PubMed Central.

³⁰ Midi Health. “Pricing & Insurance” and “Menopause Treatment.” Provider facts checked September 3, 2026. Pricing and insurance · Menopause care.

³¹ Sesame. “Online Menopause Treatment.” Provider facts checked September 3, 2026. Provider page.

³² Hers. “Does Insurance Cover HRT for Menopause?” Published prices and access description checked September 3, 2026. Provider page.